Roche is emphasizing the advantages of fixed-duration dosing for its bispecific therapies, Lunsumio and Columvi, in the competitive landscape against AbbVie/Genmab’s Epkinly for B-cell lymphomas. The outcome of ongoing Phase III studies may significantly influence market positioning.Meanwhile, Ken Mulvany has returned to lead BenevolentAI through a restructuring aimed at refocusing on its core strengths and plans to delist from Euronext Amsterdam. In another setback, Cervomed's shares plummeted nearly 80% after its lead product, neflamapimodin, failed in a Phase IIb trial for Lewy body dementia, raising questions among investors about the trial's shortcomings.
